Q1 Consolidated Revenue Down 20%, Operating Profit Plunges 93%... Treasury Shares Fully Sold

Consolidated quarterly revenue of 130.3B KRW (down 20.1% YoY), operating profit of 418M KRW (down 92.6%), net profit of 3.2B KRW (down 11.1%)
Separate operating loss of 3.3B KRW (vs operating profit of 4.2B KRW in prior year), net loss of 2.5B KRW (vs net profit of 1.9B KRW)
All 133,355 treasury shares sold on-market, resulting in a 2.7B KRW loss recognized in equity
Consolidated total borrowings of 94.8B KRW (from 90.5B at year-end), cash of 53.5B KRW, net debt ratio of 13.8%
One pending lawsuit with claim amount of 2.77B KRW, partially provisioned
R&D expenses of 14.4B KRW (10.7% of revenue); domestic approval of Zastaprazan (JP-1366) and out-licensing to China, India, Mexico, etc.
No dividend declared for the quarter (no year-end dividend for current or prior period)

ADVERTISEMENT (250px+)